Edison Investment Research - Schaltbau Holding AG (SLT) Schaltbau Holding - Termination of coverage

Report

Edison Investment Research

Toby Thorrington

Schaltbau Holding - Termination of coverage

Edison Investment Research is terminating coverage on Xintela (XINT), TXT e-solutions (TXT), HUTCHMED (HCM) and Schaltbau Holding (SLT). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

10/01/2022 1 EN

Underlying

Schaltbau Holding AG

Schaltbau Holding AG is a Germany-based company, which develops and manufactures components for transportation technology and for the investment goods industry. It operates in the following segments: Mobile Transportation Technology; Stationary Transportation Technology and Components. The Mobile Transportation Technology segment offers door systems for buses and railway vehicles, fittings for sliding vehicle doors through the Bode Group, and solutions for the controlling and monitoring of trains as well as their communication with stationary safety and signal system technologies through Albatros S.L. The Stationary Transportation Technology segment offers railway signal technology, warning systems, rail point heating systems and maritime aids to navigation through the Pintsch Group, as well as Brake Systems, which provides industrial brake and crane brake systems through the Pintsch Bubenzer Group. The Components segment offers connectors and snap-action switches, among others.

See profile

DE000A2NBTL2 Germany

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Toby Thorrington

Other Reports on these Companies

Edison Investment Research

Schaltbau Holding - Termination of coverage

January 10, 2022 January 10, 2022 1 EN

EQS Group AG

DGAP-News: Schaltbau Holding AG concludes a domination and profit and loss agreement with Voltage BidCo (Carlyle)

DGAP-News: Schaltbau Holding AG / Key word(s): Contract/Delisting Schaltbau Holding AG concludes a domination and profit and loss agreement with Voltage BidCo (Carlyle) 17.12.2021 / 16:58 The issuer is solely responsible for the content of this announcement. Schaltbau Holding AG concludes a domination and profit and loss agreement with Voltage BidCo (Carlyle) Settlement of EUR 50.33 and compensation of EUR 2.16 (gross profit contribution) per share Agreement subject to approval by the General Meeting Extraordinary General Meeting scheduled to take place on 3 Febr...

December 17, 2021 December 17, 2021 1 EN

Canadian General Investments - Adding to positive long-term performance record

Canadian General Investments (CGI) has delivered a very commendable long-term performance versus the Canadian market. Longstanding manager Greg Eckel at Morgan Meighen & Associates (MMA) is unphased by stock market volatility, following a fundamental, long-term approach to stock selection. He has taken advantage of the maximum 25% permitted allocation to US stocks to increase CGI’s returns, including a position in NVIDIA, which has been in the portfolio since 2016. The manager is unconstrained by index sector weightings and has had an underweight exposure to financial stocks for many years. Ho...

3h / 18m 3h / 18m 1 EN

Sean Conroy

Sean Conroy

Recce Pharmaceuticals - Advances on several fronts

Recce Pharmaceuticals has reported several encouraging developments in recent weeks for its lead development compound RECCE® 327 (R327). The intravenous (IV) R327 formulation is advancing to a higher dose level (4,000mg) in its ongoing Phase I/II rapid infusion study and the company is progressing in its plan to submit a US Investigational New Drug (IND) application to commence a US Phase II complicated urinary tract infection (cUTI) study before end-CY24. Recce is also planning to start an Indonesian Phase III registrational study in Q3 CY24, which we anticipate could lead to initial commerci...

5h / 8m 5h / 8m 1 EN

Toby Thorrington

Toby Thorrington

PB Holding - Net loss of €2.6m in FY23

PB Holding reported FY23 results on 26 April. The company's most important asset, the 5.3% stake in insurer for the mobility sector Bovemij, reported its FY23 results in March. Dividends from this participation are the main source of liquidity and income for PB Holding. In FY23, Bovemij paid an anniversary dividend amounting to €0.3m (FY22: €0.5m) for PB Holding. PB Holding wants to have enough liquidity to cover at least two years of its expenses (approximately €0.25m per year), which we believe is prudent. The FY23 net cash position of €0.6m could cover two to three years without dividend in...

5h / 24m 5h / 24m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Schaltbau Holding - Termination of coverage

Schaltbau Holding - Termination of coverage

DGAP-News: Schaltbau Holding AG concludes a domination and profit and loss agreement with Voltage BidCo (Carlyle)

Canadian General Investments - Adding to positive long-term performance record

Recce Pharmaceuticals - Advances on several fronts

PB Holding - Net loss of €2.6m in FY23

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe